Antinociceptive effects of meptazinol and its isomers on carrageenan-induced thermal hyperalgesia in rats

( views:60, downloads:0 )
Journal Title:
Volume 56, Issue 03, 2004
Key Word:

Abstract: Using the latency of paw withdrawal (PWL) from a noxious thermal stimulus as a measure of hyperalgesia, the effects of i.p.injection of meptazinol and its isomers, 112824 and 112825, on carrageenan-induced thermal hyperalgesia were studied in awaked carrageenan-inflamed rats. Peripheral inflammation was induced by intraplantar ( injection of carrageenan (2 mg/100 μl) into one hindpaw in rats. Carrageenan produced marked inflammation (edema and erythema) and thermal hyperalgesia in the injected paws, which peaked at 3 h after injection and showed little change in magnitude for another 3 h. Injection of 0.1 mg/kg meptazinol (i.p.) at 3 h after carrageenan had no effect on the PWLs of either inflamed or non-inflamed hindpaw during the next 100 ain (P>0.05, n=8). At the dosage of 1 and 10 mg/kg, meptazinol produced marked anti-nociception and anti-hyperalgesia in non-inflamed and inflamed hindpaw, respectively (P<0.05, n=8~1 1). The prolonging effect of meptazinol on PWL in inflamed hindpaw was more potent than that in non-inflamed hindpaw. Pre-administration of 1.5 mg/kg naloxone significantly antagonized meptazinol-induced anti-nociception and anti-hyperalgesia.Intraperitoneal injection of an isomer of meptazinol, 112825 (1.5 mg/kg), but not 112824 (1 mg/kg), markedly increased the PWL of thenon-inflamed hindpaw. Nevertheles, both the isomers produced similar anti-hyperalgesic effect to that of meptazinol (P<0.05, n=8),which was completely reversed by naloxone (1.5 mg/mg). The results suggest that meptazinol and its isomers have anti-nociceptive and anti-hyperalgesic properties with the former more potent. The effects are mainly mediated by mu opioid receptors. This study provides an important clue for extending clinical utilization of meptazinol and its isomers.

  • [1]Goode PG, White AC. Some properties of Wy 22811, a new analgesic compound. Br J Pharmacol 1971;43:462-463.
  • [2]Stephens RJ, Waterfall JF, Franklin RA. A review of the biological properties and metabolic disposition of the new analgesic agent,meptazinol. Gen Pharmacol 1978;9:73-78.
  • [3]Bill DJ, Hartley JE, Stephens RJ, Thompson AM. The antinociceptive activity of meptazinol depends on both opiate and cholinergic mechanisms. Br J Pharmacol 1983;79:191-199.
  • [4]Hoskin PJ, Hanks GW. Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs 1991;41:326-344.
  • [5]Spiegel K, Pastemak GW. Meptazinol: A novel Mu-1 selective opioid analgesic. J Pharmacol Exp Ther 1984;228:414-419
  • [6]Adler BA, Goodman RR, Pastemak GW. Quantitative autoradiographic distribution of meptazinol-sensitive binding sites in rat brain. Cell Mol Neurobiol 1988;8:471-476.
  • [7]Siegel C, Sunshine A, Richm an H, Olson NZ, Robissa N, Cordone R, Estrade N, Laska E. Meptazinol and morphine in postoperative pain assessed with a new method for onset and duration. J Clin Pharmacol 1989;29:1017-1025.
  • [8]Holmes B, Ward A. Meptazinol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1985;30:285-312.
  • [9]Franklin RA. The clinical pharmacokinetics and metabolism of the analgesic meptazinol. Xenobiotica 1988;18:105-112.
  • [10]Tzschentke TM, Bruckman W, Friderichs E. Lack of sensitization during place conditioning in rats is consistent with the low abuse potential of tramadol. Neurosci Lett 2002;329:25-28.
  • [11]Dray A, Nunan L, Wire W. Meptazinol: unusual in vivo opioid receptor activity at supraspinal and spinal sites. Neuropharmacology 1986;25:343-349.
  • [12]Winter WD, Risley EA, Nuss GW. Carrageenan-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs.Proc Soc Exp Biol Med 1962;111:544-547.
  • [13]Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983;16:109-110.
  • [14]Ji GC, Ma F, Zhang YQ, Wu GC. Thermal hyperalgesic effects induced by intracrebro ventricular injection of interleukin- 1 β in rats. Acta Physiol Sin 2002;54(4):325-328.
  • [15]Hetherington MS, Hughes IE, Lees A. An investigation of the mechanism involved in the cholinergic action of meptazinol. J Pharm Pharmacol 1987;39:185-189
  • [16]Ireson JD. A comparison of the antinociceptive actions of cholinominetic and morphine-like drugs. Br J Pharmaco11970;40:90-101.
  • [17]Lograsso M, Nadeson R, Goodchild CS. The spinal antinociceptive effects of cholinergic drugs in rats: receptor subtype specificity in different nociceptive tests. BMC Pharmaco12002;2:20.
  • [18]Peana AT, D'Aquila PS, Chessa ML, Moretti MD, Serra G, Pippia P. (-)-Linalool produces antinociception in two experimental models of pain. Eur J Pharmaco12003;460:37-41.
  • [19]Wess J, Duttaroy A, Gomeza J, Zhang W, Yamada M, FelderCC,Bemardini N, Reeh PW. Muscarinic receptor subtypes mediating central and peripheral antinociception studied with muscarinic receptor knockout mice: a review. Life Sci 2003;72:2047-2054.
  • [20]Maekawa K, Minami M, Masuda T, Satoh M. Expression of muand kappa-, but not delta-, opioid receptor mRNA is enhanced in the spinal dorsal horn of the arthritic rats. Pain 1996;64:365-371.
  • [21]Borghi V, Przewlocka B, Labuz D, Maj M, Ilona O, Pavone F.Formalin-induced pain and mu-opioid receptor density in brain and spinal cord are modulated by A1 and A2a adenosine agonists in mice. Brain Res 2002;956:339-348.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615